That's a good point. With the NASH trial expected to last 2 years you gotta think it's pivotal but Cyrus specifically said that we need to generate a large, robust and unequivocal dataset to do an accretive deal. Maybe the interim readout specified on the timeline will do for that.

He said the next call will be the quarterly update and they'll answer questions so hopefully we'll get more clarity on the path forward in March.